Masimo (NASDAQ: MASI) pushed meaningfully higher on Feb. 17 after healthcare giant Danaher (NYSE: DHR) said it will acquire the pulse oximetry leader for $180 aMasimo (NASDAQ: MASI) pushed meaningfully higher on Feb. 17 after healthcare giant Danaher (NYSE: DHR) said it will acquire the pulse oximetry leader for $180 a

Danaher stock: 3 ways Masimo deal could boost stock

2026/02/18 12:13
1 min read
Masimo (NASDAQ: MASI) pushed meaningfully higher on Feb. 17 after healthcare giant Danaher (NYSE: DHR) said it will acquire the pulse oximetry leader for $180 a share in cash. Valued at about $9.9 billion, this agreement will see Masimo go private and become a “standalone” unit within Danaher’s diagnostics segment. While MASI shareholders are enjoying an immediate payday, the real story for long-term investors lies in Danaher stock that remains down some 15% versus its year-to-date high. By swallowing a high-growth medical innovator, DHR is positioning itself for a massive re-rating as it integrates Masimo’s “sticky” hospital technology into its legendary operational engine. Why Masimo acquisition is bullish for Danaher stock Investors cheered Masimo news on Tuesday mostly because the…
Market Opportunity
Boost Logo
Boost Price(BOOST)
$0.0000987
$0.0000987$0.0000987
-32.85%
USD
Boost (BOOST) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.